Halozyme raises 2026 revenue and EPS guidance after strong third quarter
Halozyme lifted its 2026 outlook to $1.86–1.925 billion in revenue and $8.75–9.05 non-GAAP EPS, per TradingView citing PR Newswire.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Halozyme Therapeutics reported that third-quarter 2026 revenue rose 39% year over year to $493 million. Royalty revenue climbed 44% to $341 million.
On the back of these results, the company raised its full-year outlook. Revenue is now expected in a range of $1.860 to $1.925 billion, and non-GAAP diluted EPS in a range of $8.75 to $9.05. Adjusted EBITDA is projected at $1.240 to $1.290 billion, and the company has completed $400 million in share repurchases this year.
This information is based on a TradingView report citing a press release distributed by PR Newswire.
why it matters
The higher guidance rests on strong reported growth. For HALO investors, the trajectory of partner royalties, the company's main revenue driver, and results in coming quarters will show whether the new ranges hold.
market impact
HALO shares: stronger results and higher guidance support sentiment toward the stock
- Halozyme shares (HALO) pressure up — higher guidance and growing revenue and profit support sentiment around the stock
tags
instruments
on polymarket
sources
- Halozyme Therapeutics, Inc. (HALO) Raises 2026 Revenue and EPS Guidance — TradingView, 5 November 2026 at 21:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗